Director/PDMR Shareholding

RNS Number : 1467N
Yourgene Health PLC
18 January 2023
 

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Director/PDMR Shareholding

 

Manchester, UK - 18 January 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified on 16 January 2023 that Bill Chang, Chief Entrepreneur of the Company, purchased 920,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") on 13 January 2023 at a price of 0.37p per share.

 

Furthermore, the Company was notified on 17 January 2023 that Bill Chang purchased a further 13,000,000 Ordinary Shares on 17 January 2023 at a price of 0.43p per share.

 

Following the purchases, Bill Chang is interested in 302,920,1421 Ordinary Shares, representing approximately 9.53 per cent. of the Company's issued share capital.

 

1 280,000,142 Ordinary Shares are held by Changsform Innovations Pte Ltd, Bill Chang is a company director and beneficial owner of Changsform Innovations Pte Ltd.

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com  

Barry Hextall, Chief Financial Officer

 

Joanne Cross, Director of Marketing

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti




Singer Capital Markets (Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas

 

 

 

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / Mob: 07584 391 303  

 

 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises integrated genomic technologies and services enabling genomic medicine in over 60 territories. The group works in partnership with global leaders in DNA technology to advance diagnostic science and support precision medicine.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and an extension into the precision medicine space with DPYD genotyping.

 

Yourgene has a range of innovative DNA sample preparation platforms, and launched Yourgene Genomic Services in 2020, which has enabled Yourgene to offer a global laboratory service network equipped to provide high quality genetic testing and bioinformatics solutions and serve as a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr Bill Chang

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Entrepreneur

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Yourgene Health plc

b)

 

LEI

 

 

213800UUIT8BZE7QEH33

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.1p each



Identification code

ISIN: GB00BN31ZD89

 


b)

 

Nature of the transaction

 

 

Purchase of ordinary shares

 

c)

 

Price(s) and volume(s)

 

 

 

 


 

Price(s)

Volume(s)

 



0.37p

920,000



 

 

 

 

d)

 

Aggregated information




- Aggregated volume

N/A



- Price

N/A



e)

 

Date of the transaction

 

 

13 January 2023

f)

 

Place of the transaction

 

London

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr Bill Chang

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Entrepreneur

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Yourgene Health plc

b)

 

LEI

 

 

213800UUIT8BZE7QEH33

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.1p each



Identification code

ISIN: GB00BN31ZD89

 


b)

 

Nature of the transaction

 

 

Purchase of ordinary shares

 

c)

 

Price(s) and volume(s)

 

 

 

 


 

Price(s)

Volume(s)

 



0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000




0.43p

1,000,000



 

 

 

 

d)

 

Aggregated information




- Aggregated volume

13,000,000



- Price

0.43p



e)

 

Date of the transaction

 

 

17 January 2023

f)

 

Place of the transaction

 

London

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHLVLFFXFLBBBQ
UK 100

Latest directors dealings